A review of weight loss following Roux-en-Y gastric bypass vs restrictive bariatric surgery: Impact on adiponectin and insulin

Obesity Surgery

Volumn 20, Issue 5, 2010, Pages 559-568

  Butner, Katrina L ^a   Nickols Richardson, Sharon M ^b   Clark, Susan F ^a   Ramp, Warren K ^c   Herbert, William G ^a  

^a VIRGINIA POLYTECHNIC INSTITUTE AND STATE UNIVERSITY   (United States)

^b PENNSYLVANIA STATE UNIVERSITY   (United States)

^c Health Research Group LLC   (United States)

Author keywords

Adiponectin; Bariatric surgery; Insulin

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; INSULIN;

BARIATRIC SURGERY; BODY MASS; COMORBIDITY; DISEASE ASSOCIATION; HUMAN; INFLAMMATION; INSULIN RESISTANCE; INSULIN SENSITIVITY; INTERMETHOD COMPARISON; MEDICAL LITERATURE; MEDICAL RESEARCH; MEDLINE; MORBID OBESITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; POSTOPERATIVE PERIOD; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; REVIEW; ROUX Y ANASTOMOSIS; STOMACH BYPASS; TREATMENT OUTCOME; WEIGHT REDUCTION;

ADIPONECTIN; GASTRIC BYPASS; GASTROPLASTY; HUMANS; INSULIN; OBESITY, MORBID; WEIGHT LOSS;

EID: 77953286661     PISSN: 09608923     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11695-010-0089-z     Document Type: Review

References (68)

1. Taylor K. Metabolic and bariatric surgery: fact sheet. Gainesville: American Society for Metabolic and Bariatric Surgery; 2008.
2. Tice JA, Karliner L, Walsh J, et al. Gastric banding or bypass? A systematic review comparing the two most popular bariatric procedures. Am J Med. 2008; 121: 885-893
3. Shinogle JA, Owings MF, Kozak LJ. Gastric bypass as treatment for obesity: trends, characteristics, and complications. Obes Res. 2005; 13: 2202-2209
4. Guerre-Millo M. Adiponectin: an update. Diabetes Metab. 2008; 34: 12-18
5. Ballantyne GH, Gumbs A, Modlin IM. Changes in insulin resistance following bariatric surgery and the adipoinsular axis: role of the adipocytokines, leptin, adiponectin and resistin. Obes Surg. 2005; 15: 692-699 (Pubitemid 40847960)
6. Forsythe LK, Wallace JM, Livingstone MB. Obesity and inflammation: the effects of weight loss. Nutr Res Rev. 2008; 21: 117-133
7. Vetter ML, Cardillo S, Rickeis MR, et al. Narrative review: effect of bariatric surgery on type 2 diabetes mellitus. Ann Intern Med. 2009; 150: 94-103.
8. Compher C, Badellino KO. Obesity and inflammation: lessons from bariatric surgery. JPEN J Parenter Enteral Nutr. 2008; 32: 645-647
9. Holdstock C, Engstrom BE, Ohrvall M, et al. Ghrelin and adipose tissue regulatory peptides: effect of gastric bypass surgery in obese humans. J Clin Endocrinol Metab. 2003; 88: 3177-3183 (Pubitemid 36877491)
10. Couce ME, Cottarn D, Esplen J, et al. Is ghrelin the culprit for weight loss after gastric bypass surgery? A negative answer. Obes Surg. 2006; 16: 870-878 (Pubitemid 44133475)
11. Lin E, Phillips LS, Ziegler TR, et al. Increases in adiponectin predict improved liver, but not peripheral, insulin sensitivity in severely obese women during weight loss. Diabetes. 2007; 56: 735-742 (Pubitemid 46348478)
12. Vendrell J, Broch M, Vilarrasa N, et al. Resistin, adiponectin, ghrelin, leptin, and proinflammatory cytokines: relationships in obesity. Obes Res. 2004; 12: 962-971
13. Serra A, Granada ML, Romero R, et al. The effect of bariatric surgery on adipocytokines, renal parameters and other cardiovascular risk factors in severe and very severe obesity: 1-year followup. Clin Nutr. 2006; 25: 400-408 (Pubitemid 44182760)
14. Coughlin CC, Finck BN, Eagon JC, et al. Effect of marked weight loss on adiponectin gene expression and plasma concentrations. Obesity (Silver Spring). 2007; 15: 640-645
15. de Carvalho CP, Marin DM, de Souza AL, et al. GLP-I and adiponectin: effect of weight loss after dietary restriction and gastric bypass in morbidly obese patients with normal, and abnormal glucose metabolism. Obes Surg. 2009; 19: 313-320
16. Vilarrasa N, Vendrell J, Sanchez-Santos R, et al. Effect of weight loss induced by gastric bypass on proinflammatory interleukin-18, soluble tumour necrosis factor-alpha receptors. C-reactive protein and adiponectin in morbidly obese patients. Clin Endocrinol (Oxf). 2007; 67: 679-686
17. Faraj M, Havel PJ, Phelis S, et al. Plasma acylation-stimulating protein, adiponectin, leptin, and ghrelin before and after weight loss induced by gastric bypass surgery in morbidly obese subjects. J Clin Endocrinol Metab. 2003; 88: 1594-1602 (Pubitemid 36623375)
18. Garcia de laTorre N, Rubio MA, Bordiu E, et al. Effects of weight loss after bariatric surgery for morbid obesity on vascular endothelial growth factor-A, adipocytokines, and insulin. J Clin Endocrinol Metab. 2008; 93: 4276-4281
19. Trakhtenbroit MA, Leichman JG, Algahim MF, et al. Body weight, insulin resistance, and serum adipokine levels 2 years after 2 types of bariatric surgery. Am J Med. 2009; 122: 435-442
20. Swarbrick MM, Austrheim-Smith IT, Stanhope KL, et al. Circulating concentrations of high-molecular-weight adiponectin are increased following Roux-en-Y gastric bypass surgery. Diabetologia. 2006; 49: 2552-2558
21. Whitson BA, Leslie DB, Kellogg TA, et al. Adipokine response in diabetics and nondiabetics following the Roux-en-Y gastric bypass: a preliminary study. J Surg Res. 2007; 142: 295-300.
22. Whitson BA, Leslie DB, Kellogg TA, et al. Entero-endocrine changes after gastric bypass in diabetic and nondiabetic patients: a preliminary study. J Surg Res. 2007; 141: 31-39
23. Diker D, Vishne T, Maayan R, et al. Impact of gastric banding on plasma adiponectin levels. Obes Surg. 2006; 16: 1057-1061 (Pubitemid 44221272)
24. Ram E, Vishne T, Maayan R, et al. The relationship between BMI, plasma leptin, insulin and proinsulin before and after laparoscopic adjustable gastric banding. Obes Surg. 2005; 15: 1456-1462 (Pubitemid 41746422)
25. Haider DG, Schindler K, Schaller G, et al. Increased, plasma visfatin concentrations in morbidly obese subjects are reduced after gastric banding. J Clin Endocrinol Metab. 2006; 91: 1578-1581
26. Engl J, Bobbert T, Ciardi C, et al. Effects of pronounced weight loss on adiponectin oligomer composition and metabolic parameters. Obesity (Silver Spring). 2007; 15: 1172-1178 (Pubitemid 46932472)
27. Poitou C, Lacorte JM, Coupaye M, et al. Relationship between single nucleotide polymorphisms in leptin, IL6 and adiponectin genes and their circulating product in morbidly obese subjects before and after gastric banding surgery. Obes Surg. 2005; 15: 1123.
28. Kopp HP, Krzyzanowska K, Mohlig M, et al. Effects of marked weight loss on plasma levels of adiponectin, markers of chronic subclinical inflammation and insulin resistance in morbidly obese women. Int J Obes (Lond). 2005; 29: 766-771 (Pubitemid 40897012)
29. American. Dietetic Association. Evidence analysis manual: steps in the ADA evidence analysis process. Chicago: American Dietetic Association; 2008.
30. Buchwald. H. Consensus conference statement bariatric surgery for morbid obesity: health implications for patients, health professionals, and third-party payers. Surg Obes Relat Dis. 2005; 1: 371-381
31. Bloomberg RD, Fleishman A, Nalle JE, et al. Nutritional deficiencies following bariatric surgery: what have we learned? Obes Surg. 2005; 15: 145-154
32. Kotidis EV, Koliakos GG, Baltzopoulos VG, et al. Serum ghrelin, leptin and adiponectin levels before and. after weight loss: comparison of three methods of treatment-a prospective study. Obes Surg. 2006; 16: 1425-1432
33. Mari A, Manco M, Guidone C, et al. Restoration of normal glucose tolerance in severely obese patients after bilio-pancreatic diversion: role of insulin sensitivity and beta cell function. Diabetologie 2006; 49: 2136-2143
34. Despres JP, Golay A, Sjostrom. L. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med. 2005; 353: 2121-2134
35. Esposito K, Pontillo A, Di Palo C, et al. Effect of weight loss and lifestyle changes on vascular inflammatory markers in obese women: a randomized trial. JAMA. 2003; 289: 1799-1804 (Pubitemid 37430249)
36. Antuna-Puente B, Feve B, Fellahi S, et al. Adipokines: the missing link between insulin resistance and obesity. Diabetes Metab. 2008; 34: 2-11.
37. Cottam DR, Mattar SG, Barinas-Mitchell E, et al. The chronic inflammatory hypothesis for the morbidity associated with morbid obesity: implications and effects of weight loss. Obes Surg. 2004; 14: 589-600. (Pubitemid 38716577)
38. Hotta K, Funahashi T, Arita Y, et al. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol. 2000; 20: 1595-1599
39. Li S, Shin JJ, Ding EL, et al. Adiponectin levels and risk of type 2 diabetes: a systematic review and meta-analysis. JAMA. 2009; 302: 179-188
40. Abeles D, Shikora SA. Bariatric surgery: current concepts and future directions. Aesthet Surg J. 2008; 28: 79-84. (Pubitemid 351249156)
41. Buchwald H, Estok R, Fahrbach K, et al. Weight and type 2 diabetes after bariatric surgeiy: systematic review and metaanalysis. Am J Med. 2009; 122: 248-256
42. Ferner R, McGinty J, Russell C, et al. Incretins, diabetes, and bariatric surgery: a review. Surg Obes Relat Dis. 2005; 1: 589-97. discussion 97-98
43. Cummings DE, Overduin J, Foster-Schubert KE, et al. Role of the bypassed proximal intestine in the anti-diabetic effects of bariatric surgery. Surg Obes Relat Dis. 2007; 3: 109-115 (Pubitemid 46444709)
44. Garaulet M, Hernandez-Morante JJ, de Heredia FP, et al. Adiponectin, the controversial hormone. Public Health Nutr. 2007; 10: 1145-1150
45. Weyer C, Funahashi T, Tanaka S, et al. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab. 2001; 86: 1930-1935 (Pubitemid 32472900)
46. Esposito K, Giugliano G, Scuderi N, et al. Role of adipokines in the obesity-inflammation relationship: the effect of fat removal. Plast Reconstr Surg. 2006; 118: 1048-57. discussion 58-59
47. Tschritter O, Pritsche A, 'lTiamer C, et al. Plasma adiponectin concentrations predict insulin sensitivity of both glucose and lipid metabolism. Diabetes. 2003; 52: 239-243
48. Samuel I, Mason EE, Renquist KE, et al. Bariatric surgery trends: an 18-year report from the international bariatric surgery registiy. Am J Surg. 2006; 192: 657-662 (Pubitemid 44634341)
49. Pajvani UB, Hawkins M, Combs TP, et al. Complex distribution, not absolute amount of adiponectin, correlates with thiazolidinedione-mediated improvement in insulin sensitivity. J Biol Chem. 2004; 279: 12152-12162
50. Xu A, Chan KW, Hoo RL, et al. Testosterone selectively reduces the high molecular weight form of adiponectin by inhibiting its secretion from adipocytes. J Biol Chem. 2005; 280: 18073-18080
51. Pender C, Goldfine ID, Tanner CJ, et al. Muscle insulin receptor concentrations in obese patients post bariatric surgery: relationship to hyperinsulinemia. Int J Obes Relat Metab Disord. 2004; 28: 363-369
52. Gannage-Yared MH, Yaghi C, Habre B, et al. Osteoprotegerin in relation to body weight, lipid parameters insulin sensitivity, adipocytokines, and C-reactive protein in obese and non-obese young individuals: results from both cross-sectional and interventional study. Eur J Endocrinol. 2008; 158: 353-359
53. Guldstrand M, Ahren B, Adamson U. Improved beta-cell function after standardized weight reduction in severely obese subjects. Am J Physiol Endocrinol Metab. 2003; 284: E55765.
54. Engl J, Sturm W, Sandhofer A, et al. Effect of pronounced weight loss on visceral fat, liver steatosis and adiponectin isoforms. Eur J Clin Invest. 2008; 38: 238-244
55. Alverdy JC, Prachand V, Flanagan B, et al. Bariatric surgery: a history of empiricism, a future in science. J Gastrointest Surg. 2009; 13: 465-477
56. Lin E, Gletsu N, Fugate K, et al. The effects of gastric surgery on systemic ghrelin levels in the morbidly obese. Arch Surg. 2004; 139: 780-784
57. Schauer PR, Ikramuddin S, Gourash W, et al. Outcomes after laparoscopic Roux-en-Y gastric bypass for morbid obesity. Ann Surg. 2000; 232: 515-529
58. Schauer PR, Burguera B, Ikramuddin S, et al. Effect of laparoscopic Roux-en Y gastric bypass on type 2 diabetes mellitus. Ann Surg. 2003; 238: 467-84. discussion 84-85
59. Capella RF, Capella JF. Reducing early technical complications in gastric bypass surgery. Obes Surg. 1997; 7: 149-156 discussion 57.
60. Mason EE, Ito C. Gastric bypass in obesity. Surg Clin North Am. 1967; 47: 1345-1351
61. Williams MD, Champion JK. Linear technique of laparoscopic Roux-en-Y gastric bypass. Surg Technol Int. 2004; 13: 101-105
62. Fobi MA, Lee H, Igwe Jr D, et al. Revision of failed, gastric bypass to distal Roux-en-Y gastric bypass: a review of 65 cases. Obes Surg. 2001; 11: 190-195
63. Fobi MA, Lee H, Holness R, et al. Gastric bypass operation for obesity. World J Surg. 1998; 22: 925-935
64. Salmon PA. Gastroplasty with distal gastric bypass: a new and more successful weight loss operation for the morbidly obese. Can J Surg. 1988; 31: 111-113
65. MacLean LD, Rhode BM, Nohr CW Late outcome of isolated gastric bypass. Ann Surg. 2000; 231: 524-528
66. Ren CJ, Fielding GA. Laparoscopic adjustable gastric banding: surgical technique. J Laparocndosc Adv Surg Tech A. 2003; 13: 257-263
67. Mittermair RP, Weiss H, Nehoda H, et al. Laparoscopic Swedish adjustable gastric banding: 6-year follow-up and comparison to other laparoscopic bariatric procedures. Obes Surg. 2003; 13: 412-417
68. Mason EE, Doherty C, Cullen JJ, et al. Vertical gastroplasty: evolution of vertical banded gastroplasty. World. J Surg. 1998; 22: 919-924